«Antiviral compound provides full protection from Ebola
virus in nonhuman primates.»
«This is the first example of a small molecule — which can be easily prepared and made on a large scale — that shows substantive post-exposure protection against Ebola
virus in nonhuman primates,» Bavari commented.
Led by Bavari and Travis Warren, Ph.D., the USAMRIID team performed a series of studies involving a lethal challenge with Marburg
virus in nonhuman primates to determine the efficacious dose and regimen of AVI - 7288, as well as to characterize the drug exposures in animals that produced efficacy.
«Results described in this manuscript provide a comprehensive characterization of the efficacy of the PMO antisense platform against Marburg
virus in nonhuman primates and its safety profile in humans,» Bavari said.
Not exact matches
Ebola
virus causes severe hemorrhagic fever
in humans and
nonhuman primates with high mortality rates and continues to emerge
in new geographic locations, including West Africa, the site of the largest outbreak to date.
Detection and molecular characterization of Ebola
viruses causing disease
in human and
nonhuman primates
Tekmira siRNAs and ZMapp «are both head and shoulders above everything else
in terms of demonstrated efficacy
in nonhuman primates,» says Thomas Geisbert, an expert on Ebola
virus at The University of Texas Medical Branch at Galveston who has worked on most of the experimental treatments and vaccines under consideration.
This
virus, which is
in the same family as Ebola, has a rapid disease course (seven to nine days)
in nonhuman primates.
For the first time, researchers at the University of Texas Medical Branch at Galveston,
in collaboration with Tekmira Pharmaceuticals, have protected
nonhuman primates against Marburg
virus - Angola hemorrhagic fever.
«Antiviral compound protects
nonhuman primates against Marburg
virus: Safety profile also evaluated
in phase I clinical trial.»
The simian foamy
virus — so - called because of its foamy appearance under a microscope — is one of three known retroviruses
in nonhuman primates.
The sooty mangabey, found
in West Africa, has somehow adapted to the simian immunodeficiency
virus — the
nonhuman version of HIV — so that even with a high viral load, it rarely gets sick.
«Our genetic relatedness and close ecological connection to
nonhuman primates seems to predispose us to sharing
viruses — and that can happen
in both directions,» he says.
Adenoviruses, first isolated
in the 1950s from explanted adenoid tissue, are double - stranded nonenveloped DNA
viruses that naturally infect many vertebrates, including humans and
nonhuman primates.
The vaccines were evaluated for immunogenicity and efficacy; however, because of the previous report of immunopathology on challenge of ferrets and
nonhuman primates that had been vaccinated with a whole
virus adjuvanted vaccine and mice that had been vaccinated with a VLP vaccine, the primary orientation was to assess for immunopathology among animals
in relation to type of vaccine, dosage, serum antibody responses, and
virus infection.
Evaluations of an inactivated whole
virus vaccine
in ferrets and
nonhuman primates and a
virus - like - particle vaccine
in mice induced protection against infection but challenged animals exhibited an immunopathologic - type lung disease.
This experiment was conducted to verify the findings
in the initial experiment of a hypersensitivity immunopathologic - like reaction after SARS - CoV challenge of vaccinated animals, to determine if a higher dosage of the S protein vaccine (SV) would suppress infection and still exhibit a similar reaction, and whether the original β propiolactone inactivated whole
virus vaccine (BPV) that had shown an immunopathologic - like reaction after challenge of vaccinated ferrets and
nonhuman primates exhibited a similar immunopathologic reaction
in the mouse model [13], [14].
Scientists have identified potential biomarkers
in nonhuman primates exposed to Ebola
virus (EBOV) that appeared up to four days before the onset of fever, according to research published today
in the journal Science Translational Medicine.
Superior efficacy of a human immunodeficiency
virus vaccine combined with antiretroviral prevention
in simian - human immunodeficiency
virus - challenged
nonhuman primates.
Cells increase before zoster and PD - 1 expression increases at the time of zoster
in immunosuppressed
nonhuman primates latently infected with simian varicella
virus.